Sutro Biopharma STRO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $99.61M+49.9% | $102.48M+65.2% | $105.65M-34.4% | $104.47M-38.3% | $66.43M-56.9% | ||
| $151.37M-38.7% | $166.42M-34.0% | $200.81M-14.5% | $223.07M+2.2% | $246.76M+24.7% | ||
| $35.33M-27.9% | $41.02M-15.3% | $41.39M-26.4% | $46.98M-17.8% | $49.01M-18.0% | ||
| $219.12M-30.8% | $260.85M-13.2% | $291.22M+0.1% | $309.51M+12.3% | $316.81M+22.9% | ||
| -$119.51M+52.3% | -$158.37M+33.6% | -$185.58M— | -$205.04M— | -$250.38M— | ||
| -120%+257pp | -154.5%+230pp | -175.7%— | -196.3%— | -376.9%— | ||
| -$153.72M+36.7% | -$191.18M+15.1% | -$214.42M— | -$206.35M— | -$242.85M— | ||
| -$115K-105% | -$93K-104% | $2.34M-85.2% | $2.34M-86.7% | $2.37M-86.7% | ||
| -$153.6M+37.4% | -$191.09M+16.0% | -$216.77M— | -$208.7M— | -$245.22M— | ||
| -154.2%+215pp | -186.5%+180pp | -205.2%— | -199.8%— | -369.1%— | ||
| -$24.53+34.7% | -$30.67-5.4% | -$37.22— | -$37.14— | -$37.59— | ||
| -$112.81M+53.6% | -$151.04M+34.7% | -$178.01M— | -$197.57M— | -$243.02M— | ||
| -113.3%+253pp | -147.4%+225pp | -168.5%— | -189.1%— | -365.8%— | ||
| -$119.51M+52.3% | -$158.37M+33.6% | -$185.58M— | -$205.04M— | -$250.38M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $99.6M in revenue over the trailing twelve months, up 49.9% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $153.6M over the trailing twelve months, a -154.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-24.53.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
